Borges F A, Cho H S, Santos E, Oliveira G P, Costa A J
CPPAR/UNESP-São Paulo State University, FCAV, Jaboticabal, SP, Brazil.
J Vet Pharmacol Ther. 2007 Feb;30(1):62-7. doi: 10.1111/j.1365-2885.2007.00816.x.
The objective of this study was to determine the kinetic parameters of a new formulation that contained 2.25% ivermectin combined with 1.25% abamectin in bovine plasma. The results for 2.25% ivermectin: Cmax (37.11 ng/mL +/- 7.42), Tmax (16 days +/- 5.29), T(1/2) (44.62 days +/- 53.89), AUC (928.2 ng x day/mL +/- 153.83) and MRT (36.73 days +/- 33.64), and for 1.25% abamectin: Cmax (28.70 ng/mL +/- 9.54), Tmax (14 days +/- 4.04), T(1/2) (15.40 days +/- 11.43), AUC (618.05 ng x day/mL +/- 80.27) and MRT (20.79 days +/- 8.43) suggest that this combination of 2.25% ivermectin + 1.25% abamectin possesses properties that give this pharmaceutical formula a longer activity time than two of the commercial products tested (1% ivermectin and 1% abamectin), and showed similarity to 3.15% ivermectin.
本研究的目的是测定一种新制剂（含2.25%伊维菌素与1.25%阿维菌素）在牛血浆中的动力学参数。2.25%伊维菌素的结果：Cmax（37.11 ng/mL ± 7.42）、Tmax（16天 ± 5.29）、T(1/2)（44.62天 ± 53.89）、AUC（928.2 ng·天/mL ± 153.83）和MRT（36.73天 ± 33.64）；1.25%阿维菌素的结果：Cmax（28.70 ng/mL ± 9.54）、Tmax（14天 ± 4.04）、T(1/2)（15.40天 ± 11.43）、AUC（618.05 ng·天/mL ± 80.27）和MRT（20.79天 ± 8.43），这些结果表明2.25%伊维菌素 + 1.25%阿维菌素的这种组合具有使该药物配方的活性时间比两种受试商业产品（1%伊维菌素和1%阿维菌素）更长的特性，并且与3.15%伊维菌素相似。
